NIH Highlighted Topic: Behavioral and Cognitive Signals of Aging in Real-World Contexts

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institutes of Health (NIH) is encouraging innovative research focused on identifying reproducible, interpretable behavioral and cognitive signals from real-world data to advance understanding of aging, disease progression, and functional decline. This highlighted topic aims to translate computational models of temporally structured human behavior into life span developmental and aging research through the development of "cognitive vital signs" and behavioral pattern analysis.

Recent computational advances have highlighted the value of studying recurring behavioral patterns, such as sequences, transitions, and rhythms of daily activity, rather than isolated events or aggregate summary measures. NIH notes that growing interest in continuous, real-world cognitive assessment has motivated development of longitudinal indicators derived from everyday behavior, speech, and interaction patterns that complement traditional clinic-based assessments. NIH is particularly interested in projects that ensure these behavioral and cognitive signals are interpretable, robust, and valid across diverse real-world settings, populations, and contexts.

Areas of interest include characterizing recurring behavioral patterns like sleep-wake cycles, navigation routines, and social interaction rhythms as indicators of functional change with aging, developing and validating cognitive vital signs from speech, response timing, and repeated task performance, building computational methods to extract and compare temporally structured behavioral patterns, detecting early or preclinical stages of dementia through subtle daily cognition changes, identifying behavioral signals linked to cancer-related cognitive impairment and accelerated aging in survivors, and validating interpretable digital biomarkers from passive sensing and speech for mental health risk and resilience.

Note: as with prior topics, this is a Highlighted Topic rather than a standalone NOFO, so applicants apply through an appropriate NIH Parent Funding Announcement or other broad opportunity on Grants.gov rather than a dedicated solicitation with its own SBIR/STTR dollar figures.

This highlighted topic is supported primarily by the National Institute on Aging (NIA), with additional participation from the National Cancer Institute (NCI), Office of Behavioral and Social Sciences Research (OBSSR), and National Institute of Mental Health (NIMH), all of which are seeking research that translates real-world behavioral and cognitive signals into meaningful markers of aging, disease, and functional change.

How much funding would I receive?

Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.

What could I use the funding for?

Funding may support the research, development, validation, and commercialization of technologies, clinical tools, software platforms, and evidence-based interventions related to augmentative and alternative communication (AAC).

Eligible activities may include:

  • Development of speech-generating devices and AAC communication platforms

  • AI and machine learning tools for adaptive communication support

  • Personalized AAC assessment and recommendation systems

  • Precision measurement tools for tracking communication outcomes

  • Digital health platforms supporting AAC users and caregivers

  • Literacy instruction technologies for AAC users

  • Mobile applications supporting non-speaking and minimally verbal individuals

  • Predictive analytics and communication profiling systems

  • User-centered design and accessibility research for AAC technologies

  • Tools supporting communication partner engagement and training

  • Clinical software for AAC implementation and therapy management

  • Mixed-methods research platforms for communication needs analysis

  • Technologies supporting lifelong AAC adaptation and personalization

  • Remote monitoring and telehealth solutions for speech and communication therapy

  • Assistive technologies supporting autism, ALS, cerebral palsy, and related conditions

  • Research evaluating quality-of-life and well-being outcomes for AAC users

  • Prototype development, validation studies, and usability testing

  • Commercialization planning and implementation strategy development

Funding may also support personnel, software development, usability studies, clinical testing, cloud infrastructure, AI model development, accessibility design, data collection, intellectual property protection, regulatory preparation, and commercialization activities necessary to advance a scalable and commercially viable AAC solution aligned with NIH priorities.

Are there any additional benefits I would receive?

Beyond the formal funding award, awardees gain several strategic advantages:

  • Government Validation and Credibility:
    Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.

  • Enhanced Visibility and Market Recognition:
    Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.

  • Access to the Federal Innovation Ecosystem:
    Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.

  • Stronger Commercial and Exit Potential:
    By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.

What is the timeline to apply and when would I receive funding?

Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.

Where does this funding come from?

Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.

Who is eligible to apply?

Applicants must be U.S. small business concerns (SBCs) that:

  • Are organized for profit with a U.S. place of business.

  • Have ≤ 500 employees including affiliates.

  • Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.

What companies and projects are likely to win?

Projects that demonstrate:

  • A clear unmet medical or public-health need,

  • Strong scientific rationale and feasibility,

  • High commercialization potential, supported by a realistic market and regulatory strategy, and

  • Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).

Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.

Are there any restrictions I should know about?

  • Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.

  • Foreign entities are not eligible.

  • Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.

Review solicitation here.

Previous
Previous

NIH Highlighted Topic: Enhancing Data Usage and Utility to Advance Biomedical Research

Next
Next

NIH Highlighted Topic: Data Science and Artificial Intelligence Approaches for Biomedical, Biobehavioral and Social Science Research